PMID- 10821212
OWN - NLM
STAT- MEDLINE
DCOM- 20000824
LR  - 20191103
IS  - 0955-8810 (Print)
IS  - 0955-8810 (Linking)
VI  - 11
IP  - 1
DP  - 2000 Feb
TI  - Delta9-THC training dose as a determinant for (R)-methanandamide generalization 
      in rats: a systematic replication.
PG  - 81-6
AB  - Jarbe et al. (1998a) trained rats to discriminate between 
      (-)-delta9-tetrahydrocannabinol (delta9-THC) and vehicle, using different 
      training doses in order to create assays with different efficacy demands, to 
      examine whether (R)-methanandamide, an analog of the endogenous ligand 
      anandamide, had lower efficacy than delta9-THC. Rats were initially trained with 
      3 mg/kg delta9-THC, then tested with (R)-methanandamide and delta9-THC. 
      Thereafter, the rats were split into two groups and retrained with either 1.8 or 
      5.6 mg/kg delta9-THC, followed by additional tests with the two agonists. The 
      current study systematically replicated this study in two groups of rats, trained 
      from the outset to discriminate between vehicle and either 1.8 or 5.6 mg/kg 
      delta9-THC, respectively. Two-lever operant drug discrimination procedures were 
      used. The outcomes in the two studies were similar. In tests with 
      (R)-methanandamide, full substitution occurred in the low-dose delta9-THC 
      training group, whereas substitution was partial in the high-dose delta9-THC 
      training group. (R)-Methanandamide in higher doses exerted marked suppression of 
      lever pressing. In tests with delta9-THC, full substitution occurred in both 
      delta9-THC-trained groups, and rates of responding were comparable to those 
      observed during regular drug training sessions. In conclusion, both sets of data 
      indicate that cannabinoid agonists either can have varying degrees of efficacy at 
      a receptor site, or may produce their behavioral actions through multiple 
      mechanisms, or both. Prevailing training-dose condition rather than prior 
      training-dose history is the major determinant for the substitution pattern.
FAU - Jarbe, T U
AU  - Jarbe TU
AD  - MCP Hahnemann University, Department of Psychiatry, Philadelphia, USA. 
      tjarbe@astro.temple.edu
FAU - Lamb, R J
AU  - Lamb RJ
FAU - Lin, S
AU  - Lin S
FAU - Makriyannis, A
AU  - Makriyannis A
LA  - eng
GR  - DA 00253/DA/NIDA NIH HHS/United States
GR  - DA 03801/DA/NIDA NIH HHS/United States
GR  - DA 09064/DA/NIDA NIH HHS/United States
GR  - etc.
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Behav Pharmacol
JT  - Behavioural pharmacology
JID - 9013016
RN  - 0 (Arachidonic Acids)
RN  - 0 (Hallucinogens)
RN  - 150314-39-9 (methanandamide)
RN  - 7J8897W37S (Dronabinol)
SB  - IM
MH  - Animals
MH  - Arachidonic Acids/*pharmacology
MH  - Discrimination Learning/drug effects
MH  - Dose-Response Relationship, Drug
MH  - Dronabinol/*pharmacology
MH  - Generalization, Stimulus/*drug effects
MH  - Hallucinogens/*pharmacology
MH  - Male
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Reinforcement Schedule
EDAT- 2000/05/23 09:00
MHDA- 2000/08/29 11:01
CRDT- 2000/05/23 09:00
PHST- 2000/05/23 09:00 [pubmed]
PHST- 2000/08/29 11:01 [medline]
PHST- 2000/05/23 09:00 [entrez]
AID - 10.1097/00008877-200002000-00009 [doi]
PST - ppublish
SO  - Behav Pharmacol. 2000 Feb;11(1):81-6. doi: 10.1097/00008877-200002000-00009.